Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Michele B. Kaufman, PharmD, BCGP  |  Issue: February 2020, January 2020  |  December 11, 2019

ATLANTA—Based on data from a randomized clinical trial, 42% of patients with uncontrolled gout treated with pegloticase still have a therapeutic response after six months of therapy. Additionally, low to moderate levels of methotrexate or azathioprine attenuate the development of anti-drug antibodies, allowing patients to remain on therapy longer and attain a more complete therapeutic effect.

This study, presented during the 2019 ACR/ARP Annual Meeting in November, evaluated pegloticasetreated patients with uncontrolled gout in a retrospective chart review from a community rheumatology practice. The goal was to determine if immunomodulator treatment would lower the risk of anti-drug antibodies and provide a more complete treatment response for patients. Patients receiving subcutaneous or oral methotrexate were also included in the review.1 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers extracted data on patient responses, which included the duration of pegloticase therapy, gout flares, infusion reactions and methotrexate dosing. Other data included uric acid levels, liver function tests, renal function, hemoglobin and white blood cell counts. Patients’ complete blood count and comprehensive metabolic panel parameters were also closely monitored.

The Results

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Ten patients fit the study’s inclusion criteria, nine of whom were men with an average age of 52.3 years and visible tophi.

Methotrexate exposure varied, with 10 patients having received methotrexate and only one patient receiving oral methotrexate. Nine of these patients received methotrexate prior to pegloticase treatment.

At the time of data collection, five patients were complete responders, having received approximately 16 pegloticase doses for about 32 weeks. Three patients were still responding while actively receiving pegloticase, having received 10, five and two doses, respectively. One patient stopped therapy due to a loss of response and a mild infusion reaction, and another patient stopped due to a methotrexate injection-related issue. One patient required prednisone for gout flare.

Liver function test and complete blood count parameters were stable throughout therapy, except in one patient. This patient had a mild, transient alcohol-related liver function test elevation and pancytopenia that improved after treatment and stopping methotrexate use. This patient remained on pegloticase and continued on as a responder.

This small, retrospective study showed that methotrexate, when combined with pegloticase, appears to alleviate the formation of clinically significant anti-drug antibodies. The combination enables more difficult-to-treat gout patients to receive a more complete duration of pegloticase therapy.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. Albert J, Hosey T, LaMoreaux B, et al. Subcutaneous or oral methotrexate exposure and response to pegloticase in uncontrolled gout patients in a community rheumatology practice [abstract 1236]. Arthritis Rheumatol. 2019 Oct; 71(suppl 10).

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis

Related Articles
    Prokopenko Oleg / shutterstock.com

    Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

    January 10, 2022

    Prokopenko Oleg / shutterstock.com A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (metho­trexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of…

    Treatment Options for Severe Refractory Gout When Pegloticase Fails

    August 12, 2016

    Figure 2: DECT of hands #1 Pegloticase is a new alternative therapy for patients with severe, refractory gout unresponsive to other urate-lowering agents. The goal of this therapy is to reduce disease burden, tophi size and frequency of flares and to improve quality of life when other treatments have failed. Persistent lowering of plasma uric…

    Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020

    November 19, 2020

    In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences